Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO nasal timolol for epistaxis in hereditary hemorrhagic telangiectasia
2015-000385-55Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of timolol in hereditary hemorrhagic telangiectasia (HHT), sponsored by Hospices Civils de Lyon. Primary endpoint: Primary efficacy endpoint. Started Mar 2017; status: completed.
02
Drugs
timolol
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2015-000385-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000385-55.